Lessons from TGN-1412 - the impact on phase I clinical trials

IDrugs. 2007 Apr;10(4):230-2.
No abstract available

Publication types

  • Congress

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / toxicity
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Drug Industry
  • Europe
  • Humans
  • Macaca fascicularis

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • TGN-1412